Search

Background: Chronic obstructive pulmonary disease (COPD) is a cause of significant morbidity and mortality, and management of patients with this complex disease remains a challenge. Pharmacists work within an interdisciplinary health care team to coordinate services and ensure that standards of care are met. A pharmacist-initiated care bundle provided in the outpatient setting has shown promising results in improving COPD management. Objective: To evaluate, in the acute care setting, the effectiveness of a pharmacist-initiated COPD care bundle in improving compliance with health care measures known to improve outcomes in patients with COPD. Methods: This retrospective chart review included patients with acute exacerbation of COPD admitted from May 14, 2019, to February 29, 2020. Completion rates for the 6 individual components of the COPD care bundle were compared between patients who did and did not receive the pharmacist-initiated intervention. A subgroup of 22 patients received the following additional interventions: documentation of the modified Medical Research Council score, assessment of COPD medications, and vaccination review and administration. Results: A total of 106 patients were included in the analysis, 53 patients in each of the control and intervention groups. The pharmacist-initiated intervention increased completion rates for the overall COPD care bundle from 2% to 17% (p = 0.003), for provision of the COPD flare-up action plan from 4% to 79% (p < 0.001), and for provision of smoking cessation education from 0% to 36% (p = 0.04); however, there was no significant difference in assessment by a respiratory therapist. For the subgroup that received additional interventions, vaccination reviews were conducted for 21 (96%) of the 22 patients, which led to 9 (41%) receiving a guideline-recommended vaccine. Conclusions: Pharmacist involvement in initiation of the care bundle significantly increased completion rates for the activities included in the care bundle. RÉSUMÉ Contexte : La maladie pulmonaire obstructive chronique (MPOC) est une cause d’une morbidité et d’une mortalité importantes, et la prise en charge des patients atteints de cette maladie complexe demeure un défi. Les pharmaciens travaillent au sein d’une équipe interdisciplinaire de soins de santé pour coordonner les services et s’assurer du respect des normes de soins. Un ensemble de soins initié par le pharmacien en milieu ambulatoire a donné des résultats prometteurs dans l’amélioration de la prise en charge de la MPOC. Objectif : Évaluer, dans le cadre des soins aigus, l’efficacité d’un ensemble de soins pour la MPOC initié par un pharmacien pour améliorer le respect des mesures de soins de santé connues pour améliorer les résultats chez les patients atteints de MPOC. Méthodes : Cet examen rétrospectif des dossiers comprenait des patients présentant une exacerbation aiguë de la MPOC admis du 14 mai 2019 au 29 février 2020. Les taux de réussite pour les 6 composantes individuelles de l’ensemble de soins pour la MPOC ont été comparés entre les patients ayant reçu et ceux n’ayant pas reçu l’intervention initiée par le pharmacien. Un sous-groupe de 22 patients a reçu des interventions supplémentaires : documentation du score modifié du Medical Research Council (mMRC), évaluation des médicaments pour la MPOC, et examen et administration de la vaccination. Résultats : Au total, 106 patients ont été inclus dans l’analyse : 53 patients dans le groupe de contrôle et 53 dans le groupe d’intervention. L’intervention initiée par le pharmacien a augmenté les taux d’adhésion à l’ensemble de soins pour la MPOC de 2 % à 17 % (p = 0,003), de 4 % à 79 % (p < 0,001) pour l’offre du plan d’action en cas de poussée de MPOC et de 0 % à 36 % (p = 0,04) pour l’éducation au sevrage tabagique; cependant, l’évaluation par un inhalothérapeute n’a permis de déceler aucune différence significative. Dans le sous-groupe ayant reçu des interventions supplémentaires, des examens de vaccination ont été menés chez 21 (96 %) des 22 patients; 9 patients (41 %) ont ainsi reçu un vaccin recommandé par les lignes directrices. Conclusions : La participation du pharmacien à l’initiation de l’ensemble de soins a augmenté de manière significative les taux de réussite des activités incluses dans l’ensemble de soins.

This study aimed to characterize the clinical utilization of tranexamic acid (TXA) by paramedics in British Columbia (BC) for acute major trauma and to quantify the percentage of patients who received TXA among those who met the indications for administration. A quality assurance review of eligible trauma patients across the province was performed using a convenience sample. Trauma patients between April 1, 2016 and March 31, 2017 with suspected or actual hemorrhage were selected if they met inclusion criteria (systolic blood pressure 120 beats per minute) and exclusion criteria (age

This study aimed to characterize the clinical utilization of tranexamic acid (TXA) by paramedics in British Columbia (BC) for acute major trauma and to quantify the percentage of patients who received TXA among those who met the indications for administration.A quality assurance review of eligible trauma patients across the province was performed using a convenience sample. Trauma patients between April 1, 2016 and March 31, 2017 with suspected or actual hemorrhage were selected if they met inclusion criteria (systolic blood pressure 90 mm Hg ± heart rate 120 beats per minute) and exclusion criteria (age 16 years, injuries exclusively to the extremities).35 of the 100 eligible patients assessed in this review received a dose of TXA from paramedics. All 35 of the patients received TXA within 180 min of injury regardless of their original location of injury in BC (mean: 50 min; range: 15-140 min).35% of eligible patients identified in this study received TXA, which is an improvement over rates cited by previous Canadian literature. With further education opportunities for paramedics in BC and other EMS systems, there is potential to continue improving pre-hospital TXA administration rates.RéSUMé: OBJECTIFS: Cette étude visait à caractériser l’utilisation clinique de l’acide tranexamique (TXA) par les ambulanciers paramédicaux de la Colombie-Britannique pour les traumatismes aigus majeurs et à quantifier le pourcentage de patients qui ont reçu du TXA parmi ceux qui répondaient aux indications d’administration. MéTHODES: Un examen de l'assurance qualité des patients traumatisés admissibles dans toute la province a été effectué à l'aide d'un échantillon de commodité. Les patients traumatisés entre le 1er avril 2016 et le 31 mars 2017 présentant une hémorragie suspectée ou réelle ont été sélectionnés s'ils répondaient aux critères d'inclusion (pression artérielle systolique 90 mm Hg ± fréquence cardiaque 120 battements par minute) et aux critères d'exclusion (âge 16 ans, blessures exclusivement aux extrémités). RéSULTATS: 35 des 100 patients admissibles évalués dans le cadre de cet examen ont reçu une dose de TXA des ambulanciers paramédicaux. Les 35 patients ont tous reçu du TXA dans les 180 min suivant la blessure, quel que soit le lieu de leur blessure initiale en Colombie-Britannique (moyenne: 50 min; intervalle: 15 à 140 min). CONCLUSIONS: 35% des patients admissibles identifiés dans le cadre de cette étude ont reçu du TXA, ce qui représente une amélioration par rapport aux taux cités dans les publications canadiennes précédentes. Grâce aux possibilités de formation continue pour les ambulanciers en Colombie-Britannique et dans d'autres systèmes d’Aide médicale urgente (AMU), il est possible de continuer à améliorer les taux d'administration de la TXA en milieu préhospitalier.

Background: Antipsychotics have been approved for the treatment of certain psychiatric illnesses. However, these medications are also frequently used off label, and recent studies have suggested a concerning potential increase in the risk of death when used by elderly patients with dementia. Most of the available literature focusing on off-label use of antipsychotics comes from long-term care facilities; there is a lack of quantitative data for elderly patients in the acute care setting. This study was designed to examine this scenario and to identify potential quality improvement opportunities to minimize harm.Objectives: The primary objectives were to determine the prevalence of hospital-initiated off-label use of antipsychotics for elderly inpatients and to determine the plan for these drugs upon discharge. The secondary objectives included identifying the most common diagnosis and the most common agent used.Methods: A retrospective cohort study was performed with a convenience sample. Patients included in the analysis were elderly adults (≥ 65 years) who had been admitted to either of 2 medical units at a community hospital between September 1 and November 8, 2014. Descriptive statistics were used to examine prevalence patterns for the off-label use of antipsychotics. Results: A total of 250 patients were included in the analysis. Forty-five patients (18%, 95% confidence interval [CI] 13.7%–23.2%) received a hospital-initiated antipsychotic for off-label use during the admission. For 27 (60%, 95% CI 45.5%–73.0%) of these 45 patients, the off-label therapy was discontinued upon discharge or death, and for 13 (29%, 95% CI 17.7%–43.4%), the agent was continued upon discharge without a plan in place. The most frequent diagnosis was delirium, and the agent most frequently used was haloperidol.Conclusions: Off-label antipsychotic therapy was initiated for almost 1 in every 5 elderly patients receiving care in 2 medical units at a community hospital. These findings suggest a need to monitor and reassess the off-label use of these agents, especially at the time of discharge.RÉSUMÉContexte : Les antipsychotiques ont été approuvés pour le traitement de certains troubles psychiatriques. Or, ces médicaments sont aussi fréquemment utilisés en dérogation des directives de l’étiquette et des études récentes ont supposé une potentielle augmentation préoccupante du risque de décès lorsqu’ils sont employés pour traiter des patients âgés atteints de démence. La majeure partie de la littérature portant sur l’emploi non conforme d’antipsychotiques provient de centres d’hébergement et de soins de longue durée. Or, on constate un manque de données quantitatives sur les patients âgés dans les milieux de soins de courte durée. La présente étude a été conçue pour examiner ce scénario et découvrir de potentielles occasions d’amélioration de la qualité en vue de réduire au minimum les risques de préjudice.Objectifs : Les objectifs principaux étaient de déterminer la prévalence de l’emploi non conforme d’antipsychotiques amorcé à l’hôpital chez les patients aînés et de déterminer le plan relatif à la prescription de ces médicaments au moment du congé. Les objectifs secondaires incluaient de déterminer quels étaient le diagnostic le plus fréquent et le médicament le plus utilisé.Méthodes : Une étude de cohorte rétrospective a été menée à l’aide d’un échantillon de commodité. Les patients retenus pour l’analyse étaient des personnes âgées (de 65 ans et plus) ayant été admises à l’une des deux unités médicales dans un hôpital communautaire entre le 1er septembre et le 8 novembre 2014. Des statistiques descriptives ont été employées pour analyser les modèles de prévalence en ce qui concerne l’emploi non conforme d’antipsychotiques. Résultats : Au total, 250 patients ont été retenus pour l’analyse. Pendant l’hospitalisation, un antipsychotique a été amorcé hors conformité chez 45 patients (18 %, intervalle de confiance [IC] de 95 % de 13,7 % à 23,2 %). Pour 27 (60 %, IC de 95 % de 45,5 % à 73,0 %) de ces 45 patients, le traitement non conforme a été arrêté au moment du congé et, pour 13 autres (29 %, IC de 95 % de 17,7 %–43,4 %), le traitement a été poursuivi au congé sans mise en place d’un plan. Le diagnostic motivant le plus souvent l’emploi non conforme de ces médicaments était le délire et le médicament le plus employé était l’halopéridol.Conclusions : Le traitement non conforme par antipsychotique a été amorcé pendant le séjour à l’hôpital pour près d’un patient âgé sur cinq qui recevait des soins dans l’une des deux unités médicales d’un hôpital communautaire. Ces résultats laissent croire qu’une surveillance de l’emploi non conforme de ces médicaments et qu’une réévaluation d’un tel traitement sont nécessaires, particulièrement au moment du congé.

Background: Small-dose, short-interval dosing for meropenem has been shown to yield pharmacokinetic and pharmacodynamic properties similar to those associated with traditional dosing of this drug. However, few studies have examined clinical outcomes in the general population.Objectives: To characterize differences in effects between a small-dose, short-interval dosing regimen for meropenem (500 mg every 6 h) and the traditional regimen (1000 mg every 8 h) on clinical outcomes and costs to the health care system.Methods: This retrospective cohort study included 194 patients who received the traditional meropenem dosage (July 2006 to August 2008) and 188 patients who received the small-dose, short-interval regimen (December 2008 and October 2009) at a large tertiary care hospital and a community hospital. The primary outcome (clinical success), the secondary outcomes (30-day in-hospital mortality, time to defervescence, duration of therapy, and length of stay), and drug costs were compared between cohorts.Results: The 2 cohorts did not differ significantly in terms of baseline characteristics. There was no statistically significant difference between the small-dose, short-interval regimen and the traditional dosing regimen in terms of the primary outcome: clinical success was achieved in 83.5% (162/194) and 80.8% (152/188) of the patients, respectively. Likewise, there was no statistically significant difference in any of the secondary outcomes. The average drug cost per patient per visit was $222.23 with small-dose, short-interval dosing and $355.90 with traditional dosing, a significant difference of more than $130 per patient per visit.Conclusion: The small-dose, short-interval meropenem dosing regimen resulted in clinical outcomes similar to those achieved with the traditional dosing regimen at significantly lower cost. RÉSUMÉContexte : Selon des études, un schéma posologique de méropénème avec administration d’une faible dose à intervalle réduit produit des résultats pharmacocinétiques et pharmacodynamiques semblables à ceux obtenus avec une posologie traditionnelle. Mais peu d’études ont examiné les résultats cliniques dans la population générale.Objectif : Offrir un portrait des différences entre les effets d’un schema posologique de méropénème avec administration d’une faible dose à intervalle réduit (500 mg toutes les 6 heures) et d’une posologie traditionnelle (1000 mg toutes les 8 heures) pour ce qui est des résultats cliniques et des coûts pour le système de santé.Méthodes : La présente étude de cohorte rétrospective incluait 194 patients ayant reçu le méropénème selon le schéma posologique traditionnel (entre juillet 2006 et août 2008) et 188 patients l’ayant reçu avec administration d’une faible dose à intervalle réduit (entre décembre 2008 et octobre 2009) dans un grand hôpital de soins tertiaires et un hôpital communautaire. Le principal paramètre d’évaluation (succès clinique), les paramètres d’évaluation secondaires (taux de mortalité à l’hôpital dans les 30 jours, période de défervescence, durée du traitement et durée du séjour) et les coûts des médicaments ont été comparés entre les cohortes.Résultats : Les deux cohortes n’étaient pas significativement différentes en ce qui touche aux caractéristiques de base. Il n’y avait aucune difference statistiquement significative entre le schéma posologique avec administration d’une faible dose à intervalle réduit et la posologie traditionnelle en ce qui concerne le principal paramètre d’évaluation : le succès clinique a été obtenu respectivement chez 83,5 % (162/194) et chez 80,8 % (152/188) des patients. De même, aucune différence statistiquement significative n’a été relevée pour les paramètres d’évaluation secondaires. Par contre, le coût moyen des médicaments par patient par visite était de 222,23 $ pour le schéma posologique avec administration d’une faible dose à intervalle réduit et de 355,90 $ pour la posologie traditionnelle, une difference significative de plus de 130 $ par patient par visite (p < 0,001).Conclusion : Le schéma posologique de méropénème avec administration d’une faible dose à intervalle réduit produisait des résultats cliniques semblables à ceux de le posologie traditionnelle, et ce, pour un prix significativement plus faible.

Due to increasing prevalence of intracranial device use and multidrug-resistant and nosocomial organisms, central nervous system (CNS) infections requiring treatment with intraventricular (IVT) aminoglycosides are becoming increasingly common. This article systematically reviews IVT aminoglycoside literature in adults and integrates available evidence to serve as a practical reference for clinicians. Medline (1946 to December 2015), Embase (1974 to December 2015), PubMed (1966 to December 2015), Google, and Google Scholar were searched using the term aminoglycoside combined individually with the terms IVT, meningitis, shunt infection, ventriculitis, and cerebral spinal fluid. Eighteen articles were included. IVT aminoglycosides were assessed in meningitis, ventriculitis, intracranial device infections and neurosurgery prophylaxis. No serious adverse effects following IVT aminoglycoside were reported. Dosages ranged from IVT gentamicin 4–10 mg daily, IVT tobramycin 5–10 mg daily, and IVT amikacin 5–50 mg daily. Duration of therapy should be individualized; however, continuing IVT antibiotics for 3 days and up to 21 days after cerebrospinal fluid (CSF) sterilization has been reported in literature. Most studies included concomitant intravenous antibiotic use. Therapeutic drug monitoring (TDM) was reported in five studies, with varying timing of CSF concentrations obtained. No clear relationship between CSF levels and efficacy or toxicity was evident. Based on current literature, IVT aminoglycosides for the treatment of sensitive gram-negative meningitis, ventriculitis, and CNS device-associated infections appear safe and effective. Optimal dosing regimens are unclear. It is reasonable to initiate IVT aminoglycoside at lowest dose in combination with IV therapy and continuing post CSF sterilization. Preservative-free formulations should be utilized to minimize adverse drug reactions. TDM should not be routinely utilized but reserved for more complicated patients. Further pharmacokinetic and clinical trials of IVT aminoglycosides are necessary to fill current therapeutic gaps. Due to the relatively limited cases of IVT aminoglycoside utilization, prospective, randomized, controlled trials are likely not feasible, and clinicians will have to rely on data from non-randomized and/or retrospective studies.

Background. This cost-effectiveness analysis of imatinib in British Columbia Cancer Agency (BCCA) patients with advanced gastrointestinal stromal tumors (GIST) was performed to justify funding. Patients and Methods. A pragmatic, retrospective review identified BCCA patients with advanced GIST who received imatinib or historical treatment during successive, pre-specified time periods. Primary outcome was the cost-effectiveness (CE) of imatinib based on median overall survival (MOS). Secondary outcomes were cost-effectiveness based on median progression-free survival (PFS) and comparison to literature efficacy. This study took the BCCA perspective. Sensitivity analyses varying effectiveness over the 95% confidence interval (CI), cost to its extremes, discounting level at 0, 3, and 5%, and substituting life expectancy for MOS were performed. Results. Forty-six and 47 patients in the imatinib and historical groups respectively showed MOS with imatinib to be 66.7 months (95%CI 61.7— infinity) compared to 7.7 (95%CI 6.0—12.6) in the historical group. Median-PFS were 45.3 months (95%CI 24.4—infinity) and 5.6 (95%CI 3.5—8.5) respectively. Imatinib effectiveness was similar to literature reports. The annual incremental CE ratio for imatinib was $15,882 CDN per median life year gained and $23,603 CDN per median year of PFS. Conclusions. Imatinib for advanced GIST seems cost-effective in BC. Results were robust across a range of sensitivity analyses. J Oncol Pharm Practice (2008) 14: 105—112.

Objective: To perform a qualitative systematic review of the evidence comparing traditional with prolonged intermittent or continuous infusions of cefepime based on clinical and pharmacodynamic outcomes. Data Sources: PubMed (1946 to October 2014), EMBASE (1980 to October 2014), CENTRAL, Cochrane Database of Systematic Reviews, Web of Science, and International Pharmaceutical Abstracts (1970 to October 2014) were searched using the terms cefepime, pharmacokinetics, pharmacodynamics, drug administration, intravenous infusions, intravenous drug administration, continuous infusion, extended infusion, and intermittent therapy. Reference lists from relevant materials were reviewed. Study Selection and Data Extraction: Articles evaluating administration regimens of cefepime, one of which included the traditional, manufacturer-recommended 0.5-hour infusion and the other a prolonged or continuous infusion were included. Prespecified clinical outcomes of interest included all-cause mortality, length of hospital stay, clinical cure, and adverse events. The primary pharmacodynamic outcome was percentage time of unbound drug concentration remaining above the minimum inhibitory concentration. Data Synthesis: In all, 18 studies were included; 6 studies assessed clinical outcomes, and 12 assessed pharmacodynamic outcomes. Prolonged or continuous infusions of cefepime achieved the pharmacodynamic targets more often than traditional infusions. The association of improved clinical outcomes with prolonged or continuous infusions is unclear. All-cause mortality was significantly decreased with the use of a prolonged cefepime infusion in a retrospective study. Two prospective, randomized studies demonstrated no statistically significant difference in mortality between prolonged and intermittent infusions. Conclusions: The available literature on prolonged and continuous infusions of cefepime demonstrated an improved achievement of pharmacodynamic targets; however, the effect on clinical outcomes is inconclusive. Well-designed prospective studies are required to determine optimal dosing and administration strategies.

Study objectives. To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data. Results were also compared to temozolomide literature reports. Methods. A retrospective medical record review was performed to identify patients who received single agent temozolomide or lomustine during successive, prespecified time periods. Data were collected on survival, duration of therapy, drug cost, labour and supplies, and successive or prior chemotherapy. Results. Forty-one patients in the temozolomide group and 25 patients in the lomustine group were analysed. The median OS was 33.3 weeks (95% CI 28.4, 42.1 weeks) and 37.7 weeks (95% CI 25.0, 88.4 weeks) respectively ( P=0.783). Temozolomide patients received a mean of 5.1 cycles of drug treatment, with a mean cost per patient of $10 746 (CAD). In contrast, lomustine patients received a mean of 3.3 cycles of therapy, with a mean cost per patient of $129 (CAD). The cost-effectiveness analysis showed that temozolomide was generally not a cost-effective strategy and that lomustine was the dominant strategy. In the sensitivity analysis, in scenarios where median OS was prolonged with temozolomide as compared to lomustine, the incremental cost-effectiveness ratio for each life year gained ranged from $32,247 to $162,186. Conclusion. No difference in survival was observed between patients treated with single agent lomustine and temozolomide. Based on the higher cost and lack of additional clinical benefit of temozolomide, lomustine is a more cost-effective treatment strategy.

Everolimus is a novel proliferation signal inhibitor used in immunosuppressive therapies for the prevention of acute and chronic rejection. A role for everolimus drug monitoring has been suggested because of the potential for improving efficacy and reducing adverse effects. Everolimus has proven efficacy for prevention of rejection in adult de novo renal and cardiac transplant recipients. Similar effects have been shown in pediatric renal transplant patients. Several analytic methods are available to quantify everolimus concentrations. A good relationship exists between everolimus concentration and pharmacological response. Mere clinical monitoring of efficacy is insufficient because clinical presentations of graft rejection vary for each patient and are nonspecific. Thus, the authors have used a previously published 9-step decision-making algorithm to evaluate the utility of therapeutic drug monitoring for everolimus. The recommended therapeutic range for everolimus is a trough concentration of 3 to 8 ng/mL, as concentrations over 3 ng/mL have been associated with a decreased incidence of rejection, and concentrations >8 ng/mL with increased toxicity. Everolimus exhibits interindividual pharmacokinetic variability. African American patients have higher apparent clearance, whereas patients with hepatic dysfunction or those on concomitant medications with potent cytochrome P450 (CYP) 3A4 inhibitor or inducer properties have lower or higher apparent clearance, respectively. Solid organ transplant recipients will likely be maintained on immunosuppressant therapy for the life of the graft and/or recipient and thus are likely to benefit from clinical pharmacokinetic monitoring. Based on the available evidence, therapeutic drug monitoring for everolimus may provide additional information on efficacy and safety than sound clinical judgment alone. Patients on everolimus who have problems with absorption, who take concurrent cytochrome P450 inhibitors or inducers, or are noncompliant will attain the greatest benefit from drug monitoring.

Background: Pharmacy-managed warfarin dosing has been established at Burnaby Hospital, in Burnaby, British Columbia, for over 10 years. With increases in the number and acuity of patients enrolled, it has become challenging to maintain a successful anticoagulation program. The clinical pharmacy support assistant (CPSA) program was initiated to support the provision of clinical pharmacy services. At the time of the study, Burnaby Hospital had 2 CPSAs. It was anticipated that the pharmacy-managed inpatient warfarin dosing service might benefit from support through the CPSA program to maintain a consistent level of delivery. Objective: To examine the feasibility of CPSAs supporting the pharmacy-managed inpatient warfarin dosing service at Burnaby Hospital. Feasibility was based on 4 key parameters: knowledge base, accuracy of data collection, dosage recommendations, and time spent on the process. Methods: An observational, prospective pilot study was conducted over 3 months. The CPSAs were given appropriate education and training, and their performance was assessed to determine the feasibility of CPSAassisted warfarin dosing. The CPSAs had to achieve a priori target scores for each of the 4 parameters in order for CPSA-assisted warfarin dosing to be considered feasible. Results: After the didactic sections, both CPSAs answered all review questions correctly. The accuracy of data collection (based on 60 patient encounters) was 98.3%. The warfarin regimens recommended by the CPSAs were similar to those recommended by the clinical pharmacists, with doses differing by a mean of 0.46 mg. For 39 (65%) of the 60 patient encounters, the dosing recommendations of CPSAs and clinical pharmacists were identical. The average time spent per patient encounter was 10.5 min. Conclusion: With appropriate training and education, it is feasible for CPSAs to support the pharmacy-managed inpatient warfarin dosing program at Burnaby Hospital. RESUME Contexte : Un programme d’ajustement posologique de la warfarine gere par le pharmacien est en place a l’hopital Burnaby depuis plus de 10 ans. Comme le nombre de patients inscrits au programme s’accroit et que la gravite des cas augmente, il est maintenant difficile pour le programme d’anticoagulotherapie de conserver le meme niveau de performance. Le programme d’assistant au soutien de la pharmacie clinique (ASPC) a ete mis en place dans le but de soutenir la prestation de services de pharmacie clinique. Au moment de l’etude, l’hopital Burnaby avait deux ASPC. Le service d’ajustement par le pharmacien de la posologie de la warfarine des patients hospitalises pourrait beneficier du soutien du programme d’ASPC afin de conserver un niveau de prestation uniforme. Objectif : Etudier la possibilite pour les ASPC de soutenir le service d’ajustement par le pharmacien de la posologie de la warfarine des patients hospitalises offert par l’hopital Burnaby. La faisabilite etait fondee sur quatre parametres cles : la base de connaissances, l’exactitude de la collecte de donnees, les recommandations posologiques et le temps alloue au processus. Methodes : Une etude pilote prospective observationnelle a ete menee sur une periode de trois mois. Les ASPC ont obtenu un enseignement et une formation adequate et, suite a cela, leur travail a ete evalue dans le but de determiner si une aide a l’ajustement posologique de la warfarine est possible. Les ASPC devaient atteindre des scores predefinis a priori pour chacun des quatre parametres pour que leur aide a l’ajustement posologique de la warfarine soit consideree comme faisable. Resultats : Apres avoir participe aux volets didactiques, les deux ASPC ont repondu correctement a l’ensemble des questions d’evaluation. L’exactitude de la collecte de donnees (fondee sur 60 rencontres avec des patients) etait de 98,3 %. Les schemas posologiques de warfarine recommandes par les assistants etaient semblables a ceux recommandes par les pharmaciens cliniciens et variaient en moyenne de 0,46 mg. Pour 39 (65 %) des 60 rencontres avec des patients, les recommandations posologiques des assistants etaient identiques a celles des pharmaciens cliniciens. Chaque rencontre durait en moyenne 10,5 minutes. Conclusion : A l’aide d’une formation et d’un enseignement adequats, il est donc possible pour les ASPC de soutenir le programme d’ajustement par le pharmacien de la posologie de la warfarine des patients hospitalises offert par l’hopital Burnaby.

The mnemonic FASTHUG (Feeding, Analgesia, Sedation, Thromboembolic prophylaxis, Head of bed elevation, stress Ulcer prophylaxis, Glucose control) was developed by intensive care unit (ICU) physicians to ensure that key aspects of care are addressed during each patient encounter. Because this tool does not specifically target pharmacotherapy assessments, a modified version, FASTHUG-MAIDENS, was created, by changing the H to mean Hypoactive or Hyperactive delirium and adding M for Medication reconciliation; A for Antibiotics or Anti-infectives; I for Indications for medications; D for drug Dosing; E for Electrolytes, hematology, and other laboratory tests; N for No drug interactions, allergies, duplication, or side effects; and S for Stop dates.To validate the use of FASTHUG-MAIDENS as a tool for identifying drug-related problems (DRPs) in the ICU.This randomized, prospective validation study took place between January and May 2011 in the ICUs of 4 hospitals: 2 community-level ICUs and 2 tertiary referral ICUs. Each ICU had a dedicated ICU pharmacist and one or more pharmacy residents completing an ICU rotation as part of their pharmacy practice residency (total of 6 residents). The 6 pharmacy residents were randomly assigned to assess patients admitted to the ICU using FASTHUG-MAIDENS or standard monitoring practice. The mean proportion of DRPs per patient encounter identified by the residents (relative to DRPs identified by the ICU pharmacists) was the primary outcome, and the proportion of total DRPs identified in each group was assessed as a secondary end point.Pharmacy residents using the FASTHUG-MAIDENS mnemonic identified a significantly greater mean proportion of DRPs per patient encounter (73.2% versus 52.4%, p = 0.008) and a greater proportion of total DRPs (77.1% versus 52.5%, p0.001) than those assessing patients according to standard monitoring practice.In this sample, the mnemonic FASTHUG-MAIDENS was a useful tool to facilitate the capture of DRPs by pharmacy residents working in the ICU.Le code mnémonique anglaisValider l’emploi du code mnémoniqueCette étude de validation aléatoire et prospective a été menée entre janvier et mai 2011 dans les USI de quatre hôpitaux : deux USI de niveau communautaire et deux autres de référence de niveau tertiaire. Chaque USI possédait un pharmacien attitré et au moins un résident en pharmacie complétant un stage à l’USI dans le cadre de leur résidence en pratique pharmaceutique (pour un total de six résidents). Les six résidents en pharmacie ont été assignés au hasard pour évaluer les patients admis à l’USI au moyen du codeLes résidents en pharmacie qui ont utilisé le code mnémoniqueDans cet échantillon, le code mnémonique

In 2009, the College of Pharmacists of British Columbia introduced Professional Practice Policy 58, “Protocol for Medication Management—Adapting a Prescription”. This policy has enhanced pharmacy practice by allowing pharmacists to make changes to prescriptions. More specifically, it allows pharmacists to change a drug dose or formulation, titrate medications, renew prescriptions, and make drug substitutions within the same therapeutic class in all practice settings. This expansion of pharmaceutical services is in line with the objectives of CSHP 2015, increasing the extent to which pharmacists, pharmacy departments, and hospitals improve medication safety and help patients to achieve the best use of medications. An increasing number of published studies are demonstrating that an expanded scope of practice (ESP) for pharmacists improves patient outcomes and enhances pharmacists’ job satisfaction. Patient counselling, medication reconciliation (on admission, transfer, or discharge), and supplementary prescribing by pharmacists have been shown to reduce drug-related problems and readmission to hospital, thereby reducing costs for the health care system. In addition, interventions by hospital pharmacists have been linked to reductions in medication errors, medication costs, and length of hospital stay while improving medication adherence, knowledge, and appropriateness of pharmacologic therapy. Mysak and others developed a proactive practice model to facilitate provision of clinical services by pharmacists, which includes individualizing medication therapy and participating in daily bedside rounds. Those authors found that participating pharmacists felt the model improved job satisfaction and patient safety. The Clinical Executive Committee of Fraser Health endorsed expanding the scope of practice for pharmacists in 2009, and Burnaby Hospital implemented the ESP on April 1, 2012, with the aim of enhancing the timely delivery of patient care and streamlining medication reconciliation after patient admission. ESP at Burnaby Hospital consists of reordering medications for chronic conditions, initiating over-the-counter medications, changing drug formulations, changing drugs within the same therapeutic class, and titrating medication doses. This study was undertaken to determine how implementation of ESP affected pharmacy practice and patient care at Burnaby Hospital, in terms of activities performed and associated outcomes, as well as the experiences of pharmacists and physicians. The specific objective of the study was to describe and assess the impact of ESP for pharmacists at Burnaby Hospital. The primary outcomes were a categorization of the types of ESP activities performed by pharmacists and an assessment of clinical, humanistic, and economic outcomes. The secondary outcome was a description of the ESP experiences of pharmacists and the impact of ESP on physicians, as documented by surveys of these groups of healthcare professionals.

Background: Clinical pharmacy services have been shown to reduce adverse drug events and health care costs. However, few studies have assessed their effect on patient outcomes in the intensive care unit (ICU). Objective: To describe characteristics of ICU patients with documented pharmacist interventions and to evaluate the relationships between patients’ complexity level and pharmacists’ interventions and between pharmacists’ interventions and mortality rate. Methods: Inpatient records of admissions between January 1, 2004, and March 31, 2007, were analyzed to identify the presence of clinical pharmacy notes (CPNs). The characteristics of patients with and without CPNs were compared using descriptive statistics. For primary analysis of the association between patient complexity level and presence of CPNs, logistic regression modelling was performed to adjust for potential confounding. Logistic regression was also used to explore the possible association between CPNs and mortality. Finally, mortality analysis was carried out for patients with and without CPNs, with matching by complexity level. Results: The main study cohort comprised 1561 patients: 333 (21.3%) with CPNs and 1228 (78.7%) with no CPNs. A greater proportion of those with a CPN had the highest complexity level: 295 (88.6%) of those with CPNs versus 660 (53.7%) of those with no CPNs. After adjustment for age and sex, the odds ratio for having a CPN among patients with complexity level 4 (relative to patients with lower complexity levels) was 8.20 (95% confidence interval 5.44–12.38). Mortality rates were not significantly different between the 2 groups: 26.7% (89/333) among patients with CPNs and 27.9% (343/1228) among those without CPNs ( p = 0.66). After adjustment for age, sex, complexity level, and length of stay in the ICU, the presence of a CPN was not significantly associated with mortality. Mortality rates in the matched cohort ( n = 1078) were also similar between patients with and without CPNs (89/333 [26.7%] and 226/745 [30.3%], respectively; p = 0.23), and the presence of a CPN was not significantly associated with mortality after adjustments for potential confounding factors. Conclusion: Documenting clinical pharmacy activities is essential for assessing pharmacists’ impact on patient outcomes. These data suggest that ICU pharmacists prioritize clinical activities to care for the sickest patients. RESUME Contexte : Il a ete montre que les services de pharmacie clinique reduisaient les evenements indesirables lies aux medicaments et les couts de soins de sante. En revanche, peu d’etudes ont evalue leurs effets sur les resultats therapeutiques chez les patients des unites de soins intensifs (USI). Objectif : Decrire les caracteristiques des patients des USI pour lesquels les pharmaciens avaient consignes des interventions et evaluer les liens entre le niveau de complexite de l’etat des patients et les interventions des pharmaciens et entre les interventions des pharmaciens et le taux de mortalite. Methodes : Les dossiers des patients hospitalises entre le 1er janvier 2004 et le 31 mars 2007 ont ete analyses a la recherche de notes de pharmaciens cliniciens (NPC). Les caracteristiques des patients dont le dossier comportait des NPC et de ceux dont le dossier n’en comportait pas ont ete comparees au moyen de statistiques descriptives. L’analyse primaire de l’association entre le niveau de complexite de l’etat des patients et la presence de NPC a ete realisee au moyen d’un modele de regression logistique pour compenser les facteurs de confusion potentiels. Ce modele a aussi ete utilise pour evaluer l’association possible entre les NPC et la mortalite. En dernier lieu, une analyse de mortalite a compare les patients dont le dossier comportait des NPC a ceux dont le dossier n’en comportait pas, avec un appariement du niveau de complexite. Resultats : La principale cohorte de l’etude comptait 1561 patients : 333 (21,3 %) dont le dossier comportait des NPC et 1228 (78,7 %) dont le dossier n’en comportait pas. Une plus grande proportion des patients dont le dossier comportait des NPC presentaient le plus haut niveau de complexite : 295 (88,6 %) de ceux avec des NPC contre 660 (53,7 %) de ceux sans NPC. Apres ajustement pour l’âge et le sexe, le risque relatif approche de NPC chez les patients presentant un niveau de complexite 4 (par rapport aux patients presentant un niveau de complexite moindre) etait de 8,20 (intervalle de confiance a 95 % : 5,44 – 12,38). Les taux de mortalite n’etaient pas significativement differents entre les deux groupes : 26,7 % (89/333) chez les patients avec NPC et 27,9 % (343/1228) chez les patients sans NPC ( p = 0,66). Apres ajustement pour l’âge, le sexe, le niveau de complexite et la duree du sejour a l’USI, la presence d’une NPC au dossier n’etait pas associee de facon significative a la mortalite. Les taux de mortalite au sein de la cohorte appariee ( n = 1078) etaient egalement similaires entre les patients avec NPC et ceux sans NPC : respectivement 89/333 (26,7 %) et 226/745 (30,3 %) ( p = 0,23); la presence d’une NPC n’a pas ete associee de facon significative a la mortalite apres ajustements pour les facteurs de confusion potentiels. Conclusion : La consignation des activites de pharmacie clinique est essentielle a l’evaluation de l’influence des pharmaciens sur les resultats cliniques pour les patients. Ces donnees suggerent que les pharmaciens des USI accordent la priorite aux activites cliniques destinees aux soins des patients les plus malades.

Central nervous system infections requiring treatment with intraventricular (IVT) vancomycin are becoming increasingly common with advent of intracranial devices and increasing prevalence of multi-drug resistant and nosocomial organisms. Administering vancomycin via IVT route bypasses the blood-brain barrier to allow localized and controlled delivery directly to the desired site of action, achieving high concentrations for more reliable bactericidal action. This article systematically reviews current literature on IVT vancomycin in adults, compiles current knowledge, and integrates available evidence to serve as a practical reference.Medline (1946-July 2012), Embase (1974-July 2012), and International Pharmaceutical Abstracts (1970-July 2012) were searched using terms vancomycin, intraventricular, shunt infection, cerebrospinal fluid, and intraventriculitis. Seventeen articles were included in this review. Indications for IVT vancomycin included meningitis unresponsive to intravenous antibiotics, ventriculitis, and intracranial device infections. No serious adverse effects following IVT vancomycin have been reported. Dosages reported in literature ranged from 0.075-50 mg/day, with the most evidence for dosages of 5 to 20 mg/day. Duration of therapy most commonly ranged from 7 to 21 days. Therapeutic drug monitoring was reported in 11 studies, with CSF vancomycin levels varying widely from 1.1 to 812.6 mg/L, without clear relationships between CSF levels and efficacy or toxicity. Using IVT vancomycin to treat meningitis, ventriculitis, and CNS device-associated infections appears safe and effective based on current evidence. Optimal regimens are still unclear, and dosing of IVT vancomycin requires intricate consideration of patient specific factors and their impact on CNS pathophysiology. Higher-quality clinical trials are necessary to characterize the disposition of vancomycin within CNS, and to determine models for various pathophysiological conditions to facilitate better understanding of effects on pharmacokinetic and pharmacodynamic parameters.

To perform a qualitative systematic review of the evidence comparing traditional strategies against prolonged intermittent or continuous infusion strategies for piperacillin/tazobactam, based on clinical and pharmacodynamic outcomes.MEDLINE (1950-September 2011), EMBASE (1980-September 2011), and International Pharmaceutical Abstracts (1970-September 2011) were searched, using the terms piperacillin, tazobactam, pharmacokinetics, pharmacodynamics, dosing, and infusion. Reference lists from relevant publications were also reviewed.Articles evaluating the administration of piperacillin/tazobactam to adults and comparing at least 2 dosing regimens (1 of which included the traditional, manufacturer-recommended 30-minute infusion; the other, a prolonged or continuous infusion strategy) were included. Prespecified clinical outcomes of interest included mortality, clinical cures, and adverse events. The pharmacodynamic endpoint of interest was percent time of unbound drug concentration remaining above the minimum inhibitory concentration.Twelve studies were included in this review, 7 of which assessed clinical outcomes and 5 that assessed pharmacodynamic endpoints using Monte Carlo simulations. Prolonged or continuous infusions of piperacillin/tazobactam consistently achieved higher pharmacodynamic endpoints than did traditional infusions. The association of prolonged or continuous infusions with improved clinical outcomes, however, is unclear. Two retrospective studies found improved mortality rates with prolonged infusions (1 in a subgroup of patients with higher APACHE II [Acute Physiology and Chronic Health Evaluation II] scores), while another retrospective study found improved clinical cure rates with continuous infusions in patients with ventilator-associated pneumonia. These clinical benefits have not been substantiated in prospective randomized trials. No study has provided evidence of reduced adverse effects with prolonged or continuous infusions.The limited evidence available does not firmly support widespread adoption of administering piperacillin/tazobactam as prolonged intermittent or continuous infusions to improve clinical outcomes despite the achievement of higher pharmacodynamic targets in simulated studies. Retrospective studies indicate that critical care patients are the subgroup most likely to benefit from these dosing strategies. Well-designed prospective clinical trials are required to confirm potential benefits observed in retrospective studies.

Imatinib mesylate is a tyrosine kinase inhibitor used as first-line treatment in Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and metastatic or unresectable gastrointestinal stromal tumors (GIST). Therapeutic drug monitoring (TDM) for imatinib has been suggested to improve efficacy, assess compliance, and evaluate drug-drug interactions. Imatinib has proven efficacy in improving treatment response and survival in patients with Ph+ CML and GIST. Several analytical methods are available to quantify total plasma imatinib concentrations. A good relationship exists between total imatinib plasma concentrations and pharmacologic response. Clinical evaluation of pharmacologic response to imatinib alone may be insufficient given the long duration of therapy before clinical response in patients with Ph+ CML and GIST. Thus, the authors have used a previously published 9-step decision-making algorithm to evaluate the utility of TDM for imatinib. The suggested trough concentrations for improved complete cytogenetic or major molecular response in patients with Ph+ CML and improved time to progression for patients with GIST are >1000 and >1100 ng/mL, respectively. Imatinib exhibits interindividual pharmacokinetic variability. Increased apparent clearance of imatinib has been observed in chronic phase chronic myeloid leukemia and increased body weight. Decreased apparent clearance has been observed in renal impairment and patients on concomitant medications with potent inhibition of cytochrome P450 3A4. Duration of therapy in patients with Ph+ CML and GIST is lifelong. Based on the available evidence, TDM for imatinib may provide additional information on efficacy, compliance, and safety than clinical evaluation alone. Patients with suboptimal response to treatment, treatment failure, rare adverse events, drug interactions, or suspected nonadherence will attain the greatest benefit from TDM.

Background: A prolonged QTc interval on electrocardiography is often used as a surrogate marker for ventricular arrhythmia. Medications that can prolong the QTc interval may increase the risk of cardiac complications, although the exact incidence is unknown. It is reasonable to assume that administration of QTc-prolonging medications to patients with pre-existing QTc prolongation will further increase the risk of cardiac consequences. This study was designed to examine the frequency of prescription of QTc-prolonging medications in such patients and to explore the potential for clinical pharmacists to minimize the associated risks. Objectives: The primary objective was to identify the number of patients with pre-existing prolonged QTc interval for whom QTc-prolonging medications were prescribed, from among all patients with orders for QTc-prolonging medications. The secondary objectives were to determine patterns of intervention by clinical pharmacists in these cases and to document any further QTc prolongation and occurrence of cardiac events. Methods: A prospective, observational, quality assessment study was conducted over 4.5 months. Adult patients admitted to beds with cardiac monitoring by telemetry for whom one or more QTc-prolonging medications were ordered were eligible for inclusion. Patients were included if the QTc interval was longer than 450 ms on the most recent 12-lead electrocardiogram before the QTc-prolonging medication was ordered. These patients were followed to identify outcomes of interest after administration of QTc-prolonging medication. Results: Overall, a QTc-prolonging medication was prescribed for 207 patients. Of these, 53 patients (26%) had pre-existing prolongation of the QTc interval. Clinical pharmacists made recommendations related to 28 medication orders; of these, 16 (57%) were accepted by the physician. Fifty-one (96%) of the 53 patients received at least one dose of QTc-prolonging medication and were monitored daily for complications. Nine (18%) of the 51 patients who underwent daily monitoring experienced at least one cardiac event. Conclusions: A substantial proportion (26%) of patients for whom QTc-prolonging medications were prescribed had pre-existing prolongation of the QTc interval. Clinical pharmacists may have a role in reducing the risk of subsequent complications. RESUME Contexte : Le L’allongement de l’intervalle QTc a l’electrocardiogramme est souvent utilise comme critere de substitution d’arythmie ventriculaire. Les medicaments pouvant allonger l’intervalle QTc peuvent accroitre le risque de complications cardiaques, bien que l’incidence exacte demeure inconnue. On peut raisonnablement pretendre que l’administration de medicaments allongeant l’intervalle QTc chez des patients presentant un allongement preexistant de l’intervalle QTc augmentera le risque de complications cardiaques. Cette etude a ete concue pour examiner la frequence de prescription de medicaments allongeant l’intervalle QTc chez de tels patients et la possibilite pour les pharmaciens cliniciens de reduire au minimum les risques associes a cette situation. Objectifs : Le principal objectif etait de determiner le nombre de patients presentant un allongement preexistant de l’intervalle QTc a qui l’on a prescrit des medicaments allongeant cet intervalle sur l’ensemble des patients a qui l’on a prescrit des medicaments allongeant l’intervalle QTc. Les objectifs secondaires etaient de determiner les habitudes d’intervention par les pharmaciens cliniciens dans ces cas et de constater tout allongement supplementaire de l’intervalle QTc et la survenue d’evenements cardiaques. Methodes : Une etude d’evaluation qualitative, prospective et observationnelle a ete menee sur une periode de quatre mois. Les patients adultes hospitalises avec surveillance cardiaque par telemetrie au chevet et a qui l’on prescrivait au moins un medicament allongeant l’intervalle QTc etaient admissibles a l’etude. Les patients etaient admis si l’intervalle QTc objective sur le plus recent ECG a 12 derivations excedait 450 ms avant la prescription de medicaments allongeant l’intervalle QTc. Ces patients ont ete suivis afin de determiner les resultats d’interet apres l’administration de tels medicaments. Resultats : Dans l’ensemble, on a prescrit un medicament allongeant l’intervalle QTc a 207 patients. De ceux-ci, 53 (26 %) presentaient un allongement preexistant de l’intervalle QTc. Les pharmaciens cliniciens ont formule des recommandations liees a 28 des prescriptions de ces medicaments; de ces recommandations, 16 (57 %) ont ete acceptees par le medecin. De plus, 51 (96 %) des 53 patients ont recu au moins une dose de medicament allongeant l’intervalle QTc et ont fait l’objet d’une surveillance quotidienne des complications. Neuf (18%) de ces 51 patients ont presente au moins un evenement cardiaque. Conclusions : Une proportion considerable (26 %) des patients a qui l’on a prescrit un medicament allongeant l’intervalle QTc presentait un allongement preexistant de cet intervalle, ce qui porte a croire que les pharmaciens cliniciens pourraient avoir un role a jouer dans la reduction du risque de complications subsequentes.

Delirium is the most common mental disturbance in critically-ill patients and results in significant morbidity and mortality. Haloperidol is a preferred agent for the treatment of delirium in this population because of its rapid onset of action and lack of hemodynamic effects. Despite its widespread use in the critical care setting, most of the relevant data are obtained from case series or extrapolated from non-critically-ill populations. This review provides an overview of haloperidol pharmacokinetics and a comprehensive summary of the evidence for various haloperidol dosing regimens in the treatment of delirium in critically-ill patients. A comprehensive literature search was conducted in Medline, Embase, and International Pharmaceutical Abstracts with "haloperidol", "delirium", "agitation", "critically-ill", and "intensive care" as keywords. Studies involving haloperidol for delirium prophylaxis, non-critical care settings, and terminally-ill subjects were excluded. Eleven studies were identified: four with intermittent IV haloperidol, four with continuous IV infusion haloperidol, two with oral/enteral haloperidol, and one with IM haloperidol. All of the case reports, case series, and descriptive studies have shown a benefit with haloperidol, but publication bias is likely present. Only three studies were controlled studies, but all had small sample sizes and methodological flaws. Randomized, double-blind, active-comparator trials of haloperidol with allocation concealment are needed. Subsequent research should focus on using validated delirium screening and assessment scales for more objective identification and measurement of delirium outcomes.

Pharmacy practice in the intensive care unit (ICU) is complex, because of the high acuity of patients’ conditions and the large number of medications prescribed. Therefore, many pharmacists, especially those not familiar with ICU care, may feel overwhelmed and apprehensive in this setting. There is currently no standardized, structured approach to help pharmacists provide pharmaceutical care in the ICU. For that reason, routine tasks such as identifying drug-related problems are much harder to perform, and drug therapy is not always optimized. In 2005, the FASTHUG mnemonic was proposed as a standardized approach to help ICU physicians ensure that all essential aspects of care for critically ill patients are met. Implementation of the FASTHUG approach in a surgical ICU was subsequently shown to decrease the rates of ventilator-associated pneumonia. Although the mnemonic has been generally well received, some clinicians have modified it to better augment their particular ICU practices. Notably, the FASTHUG mnemonic was not designed to identify drug-related problems commonly seen in the ICU. Therefore, we developed a modified mnemonic, FASTHUG-MAIDENS, as a standardized, structured approach to identifying drug-related problems in the ICU (Table 1).

Various antiepileptics, sedative and anesthetic agents are used in the neurocritical care setting and therapeutic drug monitoring (TDM) has been proposed as a means to individualize dosing to ensure efficacy, avoid toxicity, and to account for drug-drug interactions. The purpose of this review is to highlight key articles relating to TDM published in the last 5 years with a focus on drug therapy for seizures, status epilepticus, and traumatic brain injury.Current evidence supports TDM of first-generation antiepileptics, and free-level monitoring for phenytoin and valproic acid is recommended in the neurocritical care population. There are insufficient data to recommend routine TDM of second-generation antiepileptics at this time. In traumatic brain injury, routine TDM of barbiturate infusions appears to be of little value in guiding or evaluating patient response to therapy except to differentiate between drug-induced coma and brain death. Although TDM of sedative agents has been studied, the use of clinical sedation scales is preferred over TDM in evaluating a patient's level of sedation.Therapeutic drug monitoring plays an important role in the care of patients in the neurocritical care setting but is applicable only to a limited number of drugs.

1who described the role of the data analyst technician. According to those authors, the activities of data analyst technicians in the ICU focus on retrieving data for individual patients. The information collected may include values for hemodynamic and respiratory parameters, demographic characteristics, fluid and nutritional status, and use of vasopres sors. This support activity is valuable to the delivery of pharmaceutical care in the ICU because it allows pharmacists to focus more on cognitive-based activities, which increases their overall work efficiency. However, we felt that pharmacy technicians were capable of performing more value-added activities than had previously been reported and that they could play a larger role in the ICU. We hypothesized that incorporating a clinical pharmacy support technician (CPST) program in the delivery of direct patient care in the adult tertiary-level ICU would further increase pharmacists’ work efficiency. We defined work efficiency in terms of the number of patients that the pharmacist could comprehensively assess per day and the time spent on cognitive-based activities. This article describes the CPST program at the Royal Columbian Hospital, the activities performed by the technician in the ICU, the benefits of the program, and considerations for implementing similar programs elsewhere.

Objective: To systematically review evidence comparing traditional and alternative dosing strategies for meropenem, based on clinical and pharmacoeconomic outcomes. Data Sources: MEDLINE (1950–September 2009), EMBASE (1980–September 2009), and International Pharmaceutical Abstracts (1970–September 2009) were searched, using the terms meropenem, carbapenems, pharmacodynamics, and pharmacokinetics. Reference citations from publications identified were reviewed. Study Selection And Data Extraction: Articles discussing administration of meropenem to adults with normal renal function and comparing at least 2 regimens, 1 of which included the manufacturer-recommended regimen of 0.5 g or 1 g every 8 hours infused over 30 minutes, with clinical, pharmacodynamic, or pharmacoeconomic endpoints, were included. The pharmacodynamic endpoint of interest was percent time that the unbound drug concentration exceeded the minimal inhibitory concentration for a bacterial pathogen. Data Synthesis: Sixteen studies were reviewed, which included 13 pharmacokinetic and dynamic assessments using Monte Carlo simulations, 5 clinical evaluations, and 3 pharmacoeconomic appraisals. Data on clinical and economic outcomes are largely nonrandomized retrospective analyses and case reports. Meropenem via intermittent prolonged infusion potentially increases the likelihood of achieving pharmacodynamic targets. However, a strong link with improved clinical outcomes is lacking. Smaller doses with shorter intervals appear to provide pharmacodynamic target attainment rates and clinical outcomes similar to those with traditional dosing, with potential pharmacoeconomic benefits. Meropenem via continuous infusion appears to increase the likelihood of achieving pharmacodynamic targets, compared with intermittent infusions. The sparsity of clinical evidence supporting this practice limits its broad application to practice. No studies have formally examined adverse effects with alternative dosing regimens. Conclusions: Meropenem alternative dosing strategies provide similar pharmacodynamic target attainment rates compared with traditional dosing strategies. Small doses with shorter interval dosing provide additional pharmacoeconomic benefits and similar clinical outcomes. Alternative dosing strategies for meropenem were largely studied in healthy subjects; individuals with pharmacokinetic parameters that differ significantly may be ideal subjects for empiric dose modification.

Thiopental is a barbiturate used in traumatic brain injuries (TBIs) to reduce intracranial pressure (ICP) and to manage cerebral ischemia. As thiopental follows Michaelis-Menten kinetics, therapeutic drug monitoring (TDM) has been used in practice to improve efficacy and reduce adverse effects. However, its role is still debatable, and TDM is not widely practiced. Current evidence suggests that thiopental therapy may improve mortality and functional outcome in a subpopulation of patients with severe TBI with elevated ICP refractory to conventional medical therapy. Several analytical methods are available to quantify thiopental concentrations. This review uses a previously published 9-step decision-making algorithm to determine whether TDM of thiopental in TBI is warranted. There seems to be poor correlation between thiopental concentration and pharmacological response in terms of neurological response, ICP, electroencephalography, and drug toxicity. There is no established therapeutic range for thiopental continuous infusion due to a wide range of plasma concentrations corresponding to efficacy (25-50 mg/L) and toxicity (30-70 mg/L) and the resulting overlap between the 2. Thiopental exhibits intrapatient and interpatient variability due to age, obesity, renal and hepatic dysfunction, Michaelis-Menten kinetics, and hepatic enzyme autoinduction. Available evidence suggests that TDM of thiopental continuous infusion is not beneficial in improving efficacy or avoiding toxicity. There are however 2 possible scenarios in which TDM may provide additional information to sound clinical judgment. The first is providing patient-specific plasma target concentration to guide titration of therapy. The second scenario is differentiating between brain death and barbiturate-induced coma.

We are presenting a case illustrating the complex metabolic and rhythm disturbances associated with acute clenbuterol intoxication.Clenbuterol is a long-acting beta2-adrenergic agonist primarily used in veterinary medicine in the United States. It has become a common drug of abuse by body builders because of its reported anabolic and lipolytic properties. In this case report, a body builder using veterinary clenbuterol developed significant electrolyte and cardiac manifestations.A 31-year-old man presented to the emergency department approximately 30 minutes after ingesting 1.5 ml (a tenfold dosing error) of Ventipulmin syrup (72.5 mcg/ml clenbuterol HCl). The product was brought to the emergency department (ED) by the patient. He reported no current use of anabolic steroids. He presented in an anxious state with complaints of palpitations and shortness of breath. Vital signs upon examination were as follows: BP, 122/77 mmHg (16.3/10.3 kPa); HR 254 bpm; RR, 22 bpm; Temperature, 97.1 degrees F (36 degrees C); and oxygen saturation, 100% on ambient air. His electrocardiogram (ECG) demonstrated supraventricular tachycardia with a ventricular rate of 254 bpm. Esmolol was recommended for rate control after the unsuccessful use of adenosine and diltiazem. Laboratory studies showed potassium, 2.1 mmol/L; magnesium, 1.3 mg/dL (0.54 mmol/L); phosphorus, 1.0 mg/dL (0.32 mmol/L); serum glucose, 209 mg/dL (11.6 mmol/L); creatinine, 0.8 mg/dL (70.7 micromol/L); AST, 20 U/L; ALT, 55 U/L; hemoglobin, 12.6 g/dL (126 g/L); CPK total, 87 U/L; and troponin I, 0.23 mug/L. The patient's urine was negative for any drugs of abuse. Clenbuterol levels were not obtained. A second ECG, 16 hours post ingestion, reflected atrial fibrillation with a ventricular rate of 125 to 147 bpm. On hospital day 3, he was electively cardioverted to sinus rhythm; heart rate and rhythm returned to normal, and he was discharged with oral metoprolol.Clenbuterol is approved for use in countries outside the U.S. as a bronchodilator for the treatment of acute asthma exacerbations in humans. Although clenbuterol is not a steroid hormone, it possesses anabolic properties that increase muscle mass. Its longer duration of action compared to other beta2-agonists (such as albuterol) make it a desired agent for body-building because of its high and prolonged serum level. The mechanism for the short and long-term cardiovascular complications of clenbuterol is complex. The anabolic effects of clenbuterol are associated with its beta2-adrenoreceptor agonist activity on striated skeletal muscles. In addition, clenbuterol promotes lipolysis through adipocyte beta3-adrenoreceptors.Considering the significant number of body-building enthusiasts, physicians will continue to encounter clenbuterol abuse in their clinical practices.

Etomidate has become one of the most commonly used induction agents in the United States during emergency department (ED) endotracheal intubation. While etomidate may be popular, concerns have been raised about possible adrenal suppression and subsequent adverse effects. In this paper we critically evaluate the recent literature and perspectives regarding the effect of etomidate on the adrenocortical system.

Therapeutic maximum allowable cost (MAC) is a managed care intervention that uses reference pricing in a therapeutic class or category of drugs or an indication (e.g., heartburn). Therapeutic MAC has not been studied in Canada or the United States. The proton pump inhibitor (PPI) rabeprazole was used as the reference drug in this therapeutic MAC program based on prices for PPIs in the province of Ontario. No PPI is available over the counter in Canada.To evaluate the utilization and anticipated drug cost savings for PPIs in an employer-sponsored drug plan in Canada that implemented a therapeutic MAC program for PPIs.An employer group with an average of 6,300 covered members, which adopted the MAC program for PPIs in June 2003, was compared with a comparison group comprising the book of business throughout Canada (approximately 5 million lives) without a PPI MAC program (non-MAC group). Pharmacy claims for PPIs were identified using the first 6 characters of the generic product identifier (GPI 492700) for a 36-month period from June 1, 2002, through May 31, 2005. The primary comparison was the year prior to the intervention (from June 1, 2002, through May 31, 2003) and the first full year following the intervention (June 1, 2004, through May 31, 2005). Drug utilization was evaluated by comparing the market share of each of the PPIs for the 2 time periods and by the days of PPI therapy per patient per year (PPPY) and days of therapy per prescription (Rx). Drug cost was defined as the cost of the drug (ingredient cost), including allowable provincial pharmacy markup but excluding pharmacy dispense fee. Cost savings were calculated from the allowed drug cost per claim, allowed cost per day, and allowed cost PPPY.(All amounts are in Canadian dollars.) The MAC intervention group experienced an 11.7% reduction in the average cost per day of PPI drug therapy, from 2.14 US dollars in the preperiod to 1.89 US dollars in the postperiod, compared with a 3.7% reduction in the comparison group (2.16 US dollars vs. 2.08 US dollars). Utilization dropped by 11.9% in the intervention group, from 166.7 days of PPI drug therapy PPPY to 146.9 days PPPY, compared with an increase of 7.9% in the comparison group, from 136.1 days to 146.8 days PPPY. The combined effect of the decrease in drug cost per day and utilization was a 22.1% reduction in allowed drug cost PPPY in the intervention (MAC) group (from 357 US dollars to 278 US dollars PPPY) versus a 4.1% increase in the comparison group (from 293 US dollars to 305 US dollars PPPY).A MAC program for PPIs for one employer in Canada was associated with savings for the drug plan sponsor of approximately 8% in actual drug cost per day of therapy compared with the comparison group. Total savings after consideration of utilization was approximately 26% for the intervention group versus the comparison group.